You can get by with less.

A new study by the Swiss Cancer Institute, led by Dr. Roger von Moos, shows that denosumab—a drug used to treat bone metastases—is just as effective when administered three times less frequently, and actually causes fewer side effects. What does this mean in practice?

For patients: less stress, fewer side effects, and fewer hospital visits

For the healthcare system: over 50% lower costs per treatment and potential savings of around CHF 15 million per year in Switzerland alone

This example clearly demonstrates what therapy optimization studies can achieve: effective, safe, and at the same time more efficient treatments. This is what the Swiss Cancer Institute is committed to.

However, Switzerland lacks the funding and appropriate framework conditions for such studies. The fact that the denosumab study was co-funded by CSS, Helsana, and prio.swiss is a first. Thank you for your support!

The result: While the number of clinical cancer studies in Switzerland has been stagnating for years, it is growing worldwide especially in China. If Switzerland cannot keep pace, it will lose not only scientific influence but also the ability to actively shape treatment standards, as our CEO Vincent Gruntz emphasizes.

Our commitment is clear: We are dedicated to ensuring that such studies take place in Switzerland, for high-quality and financially sustainable healthcare.

Article in SonntagsBlick

About the study